Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231

BMC Clinical Pharmacology

Gabriela Martín¹  Rosa Bergoc²  Elena Rivera¹  Claudia Cocca¹  Máximo Croci³  Graciela Cricco¹  Vanina Medina¹  Mariel Núñez¹ 

[1]Radioisotopes Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina

[2]Institute of Health Sciences Barceló, Buenos Aires, Argentina

[3]Institute of Immunooncology Dr. EJV Crescenti, Buenos Aires, Argentina

关键词: Cytostatic effect;    MDA-MB-231;    Potassium channels;    Glibenclamide;   

Others  :  860668
DOI  :  10.1186/2050-6511-14-6

 received in 2012-03-31, accepted in 2013-01-07,  发布年份 2013

【 摘 要 】

Background

Glibenclamide (Gli) binds to the sulphonylurea receptor (SUR) that is a regulatory subunit of ATP-sensitive potassium channels (K_ATP channels). Binding of Gli to SUR produces the closure of K_ATP channels and the inhibition of their activity. This drug is widely used for treatment of type 2-diabetes and it has been signaled as antiproliferative in several tumor cell lines. In previous experiments we demonstrated the antitumoral effect of Gli in mammary tumors induced in rats. The aim of the present work was to investigate the effect of Gli on MDA-MB-231 breast cancer cell proliferation and to examine the possible pathways involved in this action.

Results

The mRNA expression of the different subunits that compose the K_ATP channels was evaluated in MDA-MB-231 cells by reverse transcriptase-polymerase chain reaction. Results showed the expression of mRNA for both pore-forming isoforms Kir6.1 and Kir6.2 and for the regulatory isoform SUR2B in this cell line. Gli inhibited cell proliferation assessed by a clonogenic method in a dose dependent manner, with an increment in the population doubling time. The K_ATP channel opener minoxidil increased clonogenic proliferation, effect that was counteracted by Gli. When cell cycle analysis was performed by flow cytometry, Gli induced a significant cell-cycle arrest in G0/G1 phase, together with an up-regulation of p27 levels and a diminution in cyclin E expression, both evaluated by immunoblot. However, neither differentiation evaluated by neutral lipid accumulation nor apoptosis assessed by different methodologies were detected. The cytostatic, non toxic effect on cell proliferation was confirmed by removal of the drug.

Combination treatment of Gli with tamoxifen or doxorubicin showed an increment in the antiproliferative effect only for doxorubicin.

Conclusions

Our data clearly demonstrated a cytostatic effect of Gli in MDA-MB-231 cells that may be mediated through K_ATP channels, associated to the inhibition of the G1-S phase progression. In addition, an interesting observation about the effect of the combination of Gli with doxorubicin leads to future research for a potential novel role for Gli as an adjuvant in breast cancer treatment

【 授权许可】

   
2013 Núñez et al.

【 图 表 】

【 参考文献 】

• [1]Krentz AJ, Bailey CJ: Oral antidiabetic agents. Current role in type 2 diabetes. Drugs 2005, 65:385-411.
• [2]Lebovitz HE: Treating hyperglycemia in type 2 diabetes: new goals and strategies. Cleve Clin J Med 2002, 69:809-820.
• [3]Lebovitz HE: Oral antidiabetic agents. Med Clin North Am 2004, 88:847-863.
• [4]Shorter K, Farjo NP, Picksley SM, Randall VA: Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J 2008, 22:1725-1736.
• [5]Groop LC: Sulphonylureas in NIDDM. Diabetes Care 1992, 15:737-754.
• [6]Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS: Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(−) channels and intracellular Ca(2+) release in HepG2 human hepatoblastoma cells. Biochem Biophys Res Commun 1999, 261:682-688.
• [7]Qian X, Li J, Ding J, Wang Z, Duan L, Hu G: Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol 2008, 76:1705-1715.
• [8]Wonderlin WF, Strobl JS: Potassium channels, proliferation and G1 progression. J Membr Biol 1996, 154:91-107.
• [9]Pardo LA: Voltage-gated potassium channels in cell proliferation. Physiology 2004, 19:285-292.
• [10]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [11]Al-Dhaheri MH, Shah YM, Basrur V, Pind S, Rowan BG: Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells. Steroid 2006, 71:966-978.
• [12]Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC: Early breast cancer. Lancet 2009, 373:1463-1479.
• [13]Utsumi T, Kobayashi N, Hanada H: Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 2007, 14:194-199.
• [14]Jordan VC, Brodie AM: Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007, 72:7-25.
• [15]Park BJ, Whichard ZL, Corey SJ: Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines–lessons for design of combination targeted therapy. Cancer Lett 2012, 320:104-110.
• [16]Smith L, Watson MB, O’Kane SL, Drew PJ, Lind MJ, Cawkwell L: The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006, 5:2115-2120.
• [17]Joensuu H, Gligorov J: Adjuvant treatments for triple-negative breast cancers. Ann Oncol 2012, 23:vi40-vi45.
• [18]Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R: Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 2004, 68:1345-1352.
• [19]Mody M, Dharker N, Bloomston M, Wang PS, Chou FS, Glickman TS, McCaffrey T, Yang Z, Pumfery A, Lee D, Ringel MD, Pinzone JJ: Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer 2007, 14:305-315.
• [20]Jovanović S, Du Q, Mukhopadhyay S, Swingler R, Buckley R, McEachen J, Jovanović A: A patient suffering from hypokalemic periodic paralysis is deficient in skeletal muscle ATP-sensitive K channels. Clin Transl Sci 2008, 1:71-74.
• [21]Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [22]Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al.: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995, 92:9363-9367.
• [23]Greespan P, Mayer E, Fowler S: Nile Red: A selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985, 100:965-973.
• [24]Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S: Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-x(L), without alteration of p53 protein levels. Clin Cancer Res 1999, 5:2971-2977.
• [25]Mohamad N, Gutiérrez A, Núñez M, Cocca C, Martín G, Cricco G, Medina V, Rivera E, Bergoc R: Mitochondrial apoptotic pathways. Biocell 2005, 29:149-161.
• [26]Schmitt E, Paquet C, Beauchemin M, Bertrand R: DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B 2007, 8:377-397.
• [27]Davis T, Kennedy C, Chiew YE, Clarke CL, De Fazio A: Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 2000, 6:4334-4342.
• [28]Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martínez-Mármol R, Solé L, Ferreres JC, Condom E: Potassium channels: new targets in cancer therapy. Cancer Detect Prev 2006, 30:375-385.
• [29]Martin G, Melito G, Rivera E, Levin E, Davio C, Cricco G, Andrade N, Caro R, Bergoc R: Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. Cancer Lett 1996, 100:227-234.
• [30]Martin G, Rivera ES, Daivo C, Cricco G, Levin E, Cocca C, Andrade N, Caro R, Bergoc RM: Receptors characterization of intraperitoneally N-nitroso-N-methylurea-induced mammary tumors in rats. Cancer Lett 1996, 101:1-8.
• [31]Cocca C, Martín G, Núñez M, Gutiérrez A, Cricco G, Mohamad N, Medina V, Croci M, Crescenti E, Rivera E, Bergoc R: Effect of glibenclamide on N-nitroso-methylurea-induced mammary tumors in diabetic and nondiabetic rats. Oncology Res 2005, 15:301-311.
• [32]Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Diers AR, Edmonds MD, Kirsammer GT, Landar A, Welch DR: Subsets of ATP-sensitive potassium channel (KATP) inhibitors increase gap junctional intercellular communication in metastatic cancer cell lines independent of SUR expression. FEBS Lett 2012, 586:27-31.
• [33]Du Q, Jovanović S, Sukhodub A, Barratt E, Drew E, Whalley KM, Kay V, McLaughlin M, Telfer EE, Barratt CL, Jovanović A: Human oocytes express ATP-sensitive K(+) channels. Hum Reprod 2010, 25:2774-2782.
• [34]Ouadid-Ahidouch H, Ahidouch A: K + channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol 2008, 221:1-6.
• [35]Jang SS, Park J, Hur SW, Hong YH, Hur J, Chae JH, Kim SK, Kim J, Kim HS, Kim SJ: Endothelial progenitor cells functionally express inward rectifier potassium channels. Am J Physiol Cell Physiol 2011, 301:C150-C161.
• [36]Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS: Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol 1995, 162:163-171.
• [37]Malhi H, Irani AN, Rajvanshi P, Suadicani SO, Spray DC, McDonald TV, Gupta S: KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem 2000, 275:26050-26057.
• [38]Abdul M, Santo A, Hoosein N: Activity of potassium channel-blockers in breast cancer. Anticancer Res 2003, 23:3347-3351.
• [39]Huang W, Acosta-Martínez M, Levine JE: Ovarian steroids stimulate adenosine triphosphate-sensitive potassium (KATP) channel subunit gene expression and confer responsiveness of the gonadotropin-releasing hormone pulse generator to KATP channel modulation. Endocrinology 2008, 149:2423-2432.
• [40]Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Ther 2002, 1:226-231.
• [41]Gladden AB, Diehl JA: Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005, 96:906-913.
• [42]Möröy T, Geisen C: Cyclin E. Int J Biochem Cell Biol 2004, 36:1424-1439.
• [43]Conradie R, Bruggeman FJ, Ciliberto A, Csikász-Nagy A, Novák B, Westerhoff HV, Snoep JL: Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex. FEBS J 2010, 277:357-367.
• [44]Eto I: Upstream molecular signaling pathways of p27(Kip1) expression in human breast cancer cells in vitro: differential effects of 4-hydroxytamoxifen and deficiency of either D-(+)-glucose or L-leucine. Cancer Cell Int. 2011, 11:31. BioMed Central Full Text
• [45]Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA: Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007, 13:5488-5496.
• [46]Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y: Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000, 271:422-428.
• [47]You H, Yu W, Sanders BG, Kline K: RRR-α-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Diff 2001, 12:471-480.
• [48]Münster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001, 61:2945-2952.
• [49]Fattman CL, An B, Sussman L, Dou QP: p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Lett 1998, 130:103-113.
• [50]Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999, 79:257-263.
• [51]Mandlekar S, Yu R, Tan TH, Kong AN: Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 2000, 60:5995-6000.
• [52]Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ: A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 2008, 99:1056-1063.
• [53]Zhang X, Ding L, Kang L, Wang ZY: Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One 2012, 7:e30174.
• [54]Chen JH, Ling R, Yao Q, Li Y, Chen T, Wang Z, Li KZ: Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer 2005, 12:93-100.
• [55]Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 2001, 132(3):778-784.
• [56]Lee I, Park C, Kang WK: Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence. Mol Cancer Ther 2010, 9(11):2951-2959.